OncoZenge

5.95 SEK

+2.41 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+2.41 %
+0.85 %
+11.21 %
-11.98 %
+4.75 %
+27.96 %
-33.07 %
-41.67 %
-51.38 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Read more
Market cap
83.59M SEK
Turnover
180.33K SEK
Revenue
2.66M
EBIT %
-592.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/5
2026

Interim report Q1'26

27/5
2026

General meeting '26

27/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.